HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison

Journal of Cancer Research and Clinical Oncology

Volumn 141, Issue 8, 2015, Pages 1343-1351

  Koopman, T ^a   Smits, M M ^a   Louwen, M ^a   Hage, M ^a   Boot, H ^b   Imholz, A L T ^a  

^a DEVENTER HOSPITAL   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Esophageal cancer; Gastric cancer; Gastroesophageal cancer; Human epidermal growth factor 2 (HER2); Primary tumor location

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; RECEPTOR, ERBB-2;

ADVANCED CANCER; AGED; ARTICLE; CHROMOGENIC IN SITU HYBRIDIZATION; COMPARATIVE STUDY; DISEASE SEVERITY; ESOPHAGEAL ADENOCARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STOMACH ADENOCARCINOMA; ADENOCARCINOMA; ADULT; AGED, 80 AND OVER; ESOPHAGEAL NEOPLASMS; GENE DOSAGE; GENETICS; HUMANS; METABOLISM; MIDDLE AGED; PATHOLOGY; STOMACH NEOPLASMS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ESOPHAGEAL NEOPLASMS; FEMALE; GENE DOSAGE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 84931576697     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1900-3     Document Type: Article

References (55)

1. American Cancer Society (2011) Global cancer facts and figures, 2nd edn. American Cancer Society, Atlanta
2. Bang Y, Chung H, Xu J et al (2009) Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol 27:15s (suppl; abstr 4556)
3. Bang YJ, van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2 positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697
4. Bhargava R, Lal P, Chen B (2005) Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low level amplification: does it measure up to fluorescence in situ hybridization? Am J Clin Pathol 123:237–243
5. Bokemeyer C, Bondarenko I, Hartmann JT et al (2011) Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22:1535–1546
6. Chau I, Norman AR, Cunningham D et al (2009) The impact of primary tumour origins in patients with advanced oesophageal, oesophago–gastric junction and gastric adenocarcinoma—individual patient data from 1775 patients in four randomised controlled trials. Ann Oncol 20:855–891
7. Chua TC, Merrett ND (2012) Clinicopathological factors associated with HER2-positive gastric cancer and its impact on survival outcomes—a systematic review. Int J Cancer 130:2845–2856
8. Derakshan MH, Liptrot S, Paul J et al (2009) Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females. Gut 58:16–23
9. Douillard JY, Siena S, Cassidy J et al (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28:4697–4705
10. Edge SB, Byrd DR, Compton CC et al (eds) (2010) AJCC cancer staging manual, 7th edn. Springer, New York, pp 103–125
11. Garcia M, Jemal A, Ward EM et al (2007) Global cancer facts and figures 2007. American Cancer Society, Atlanta
12. Gaur P, Hofstetter WL, Bekele BN et al (2010) Comparison between established and the worldwide esophageal cancer collaboration staging systems. Ann Thorac Surg 89:1797–1804
13. Gómez-Martin C, Garralda E, Echarri MJ et al (2012) HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer. J Clin Pathol 65(8):751–757
14. Gordon MA, Gundacker HM, Benedetti J et al (2013) Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 24:1754–1761
15. Grabsch H, Sivakumar S, Gray S et al (2010) HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value—conclusions from 924 cases of two independent series. Cell Oncol 32:57–65
16. Gravalos C, Jimeno A (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19:1523–1529
17. Heidl G, Langhans P, Mellin W et al (1993) Adenocarcinomas of esophagus and cardia in comparison with gastric carcinoma. J Cancer Res Clin Oncol 120:95–99
18. Hofmann M, Stoss O, Shi D et al (2008) Assessment of a HER2 scoring system for gastric cancer: results from a validation study
19. Horner MJ, Ries LAG, Krapcho M et al (2012) SEER cancer statistics review, 1975–2009. http://seer.cancer.gov/csr/1975_2009/. Accessed 12 Dec 2012
20. Hu Y, Bandla S, Godfrey TE et al (2011) HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma. Mod Pathol 24:899–907
21. Jaehne J, Urmacher C, Thaler HT et al (1992) Expression of Her2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma. J Cancer Res Clin Oncol 118:474–479
22. Janjigian YY, Werner D, Pauligk C et al (2012) Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol 23(10):2656–2662
23. Kamangar F, Dores GM, Anderson WF et al (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137–2150
24. Kiyose S, Igarashi H, Nagura K et al (2012) Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Pathol Int 62(11):728–734
25. Langer R, Rauser S, Feith M et al (2011) Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation. Mod Pathol 24:908–916
26. Laurén P (1965) The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64:31–49
27. Lordick F, Kang YK, Chung HC et al (2013) Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 14:490–491
28. Park DI, Yun JW, Park JH et al (2006) HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 51:1371–1379
29. Pera M, Manterola C, Vidal O et al (2005) Epidemiology of esophageal adenocarcinoma. J Surg Oncol 92:151–159
30. Phillips BE, Tubbs RR, Rice TW et al (2012) Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction. Dis Esophagus. doi:10.1111/j.1442-2050.2012.01369.x
31. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1672
32. Pirker R, Pereira JR, Szczesna A, The FLEX Study Team et al (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomized phase III trial. Lancet 373:1525–1531
33. Reichelt U, Duesedau P, Tsourlakis MC et al (2007) Frequent homogeneous HER-2 amplification in primary and metastastic adenocarcinoma of the esophagus. Mod Pathol 20:120–129
34. Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684
35. Rossi E, Grisanti S, Villanacci V et al (2009) HER-2 overexpression/amplification in Barrett’s oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study. J Cell Mol Med 13(9 B):3826–3833
36. Rossi E, Villanacci V, Bassotti G et al (2006) Her-2/neu in Barrett esophagus: a comparative study between histology, immunohistochemistry, and fluorescence in situ hybridization. Diagn Mol Pathol 15(3):125–130
37. Rüschoff J, Dietel M, Baretton G et al (2010) HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing. Virchows Arch 457:299–307
38. Rüschoff J, Hanna W, Bilous M et al (2012) HER2 testing in gastric cancer: a practical approach. Mod Pathol 25(5):637–650
39. Santini D, Vincenzi B, Pantano F et al (2013) ‘All action no talk’: the role of HER2/neu in adjuvant therapy choice for gastric cancer. Ann Oncol 24:1715–1717
40. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792
41. Smith I, Procter M, Gelber RD et al (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369(9555):29–36
42. Sobin LH, Wittekind C (2002) TNM classification of malignant tumours, 6th edn. Wiley, Hoboken
43. Sobin LH, Gospodarowicz M, Wittekind C, International Union Against Cancer (UICC) (eds) (2010) TNM classification of malignant tumours, 7th edn. Wiley, Hoboken
44. Song Y, Huang J, Wang JW (2010) Correlation of HER-2/neu gene amplification and protein expression with the prognosis of advanced gastric cancer patients. Chin J Cancer 29(1):76–81
45. Talsma K, van Hagen P, Grotenhuis BA et al (2012) Comparison of the 6th and 7th editions of the UICC–AJCC TNM Classification for Esophageal Cancer. Ann Surg Oncol 19:2142–2148
46. Tanner T, Gancberg D, di Leo A et al (2000) Chromogenic in situ hybridization. A practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 157(5):1467–1472
47. Tanner M, Hollmen M, Junttila TT et al (2005) Amplification of HER-2 in gastric carcinoma: association with Topiosomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16:273–278
48. Van Cutsem E, Kohne CH, Lang I et al (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011–2019
49. Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127
50. Wadell T, Chau I, Cunningham D et al (2013) Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 14:481–489
51. Wagner AD, Grothe W, Haerting J et al (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903–2909
52. Warneke VS, Behrens HM, Böger C et al (2013) Her2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann Oncol 24(3):725–733
53. Yoon HH, Shi Q, Sukov WR et al (2012a) Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. J Clin Oncol 30:3932–3938
54. Yoon HH, Shi Q, Sukov WR et al (2012b) Association of HER2/ErbB2 expression and gene amplification with pathological features and prognosis in esophageal adenocarcinomas. Clin Cancer Res 18:546–554
55. Yu GZ, Chen Y, Wang JJ (2009) Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. J Cancer Res Clin Oncol 135:1331–1339